"Global Genetic Testing Market Forecast to 2015", provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principal, types and Direct-to-Consumer (DTC) business methodology is also covered in around 140-page report. On account of our analysis of the past and present market trends, drivers, and existing strengths and challenges, forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 26% during 2012-2015.

The report effectively illustrates the role of genetic testing in diseases, such as Cancer, Cystic Fibrosis, and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely: Next-Generation Sequencing and Genomic Biomarkers are found inside the report.

The report provides comprehensive analytics of key developments for major markets including the US, Canada, the UK, and Germany. These key developments are likely to set the future of genetic testing market in these countries and that is precisely the reason behind their incorporation in the report.

The report also profiles the eight most active genetic testing market players worldwide: Abbott Laboratories, Beckman Coulter, Roche Diagnostics, Myriad Genetics, Life Technologies, Genomic Health, Sequenom, Transgenomic, Dako, Gen-Probe, Quest Diagnostics, Genoptix and Clarient. For the purpose of effective competitive analysis of the market, these companies are analyzed on five major areas namely: business overview, product offering; financial performance for the last three years, strategic analysis of strengths and weaknesses and key developments.

Table Of Contents

1. Analyst View
2. Research Methodology
3. Introduction to Genetic Testing
4. Global Genetic Testing Market Overview
4.1 Market Outlook
4.2 Genetic Testing Laboratories - Unmet Need Analysis
4.3 DTC Genetic Testing
5. Disease-Wise Analysis
5.1 Alzheimer's Disease
5.2 Cystic Fibrosis
5.3 Cancer
6. Country-Level Analysis
6.1 US
6.1.1 Companion Diagnostics and LDTs
6.1.2 Economical and Social Impact
6.1.3 Regulatory Measures
6.1.4 Step towards DTC Genetic Tests Regulation
6.1.5 Research and Studies
6.2 Canada
6.2.1 World's First Bedside Genetic Test
6.2.2 Physicians’ Opinion
6.2.3 Information Privacy
6.3 UK
6.3.1 Role of NICE
6.3.2 Newborn Screening: Five Rare Inherited Diseases
6.4 Germany
6.4.1 Pre-implantation Genetic Diagnosis
6.4.2 RAD51C Mutation Screening
7. Emerging Sectors
7.1 Next-Generation Sequencing
7.2 Genomic Biomarkers
8. Competitive Assessment
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Product Offering
8.1.3 Financial Overview
8.1.4 Key Activities
8.1.5 Strengths and Weaknesses
8.2 Beckman Coulter
8.2.1 Company Overview
8.2.2 Product Offering
8.2.3 Financial Overview
8.2.4 Key Activities
8.2.5 Strengths and Weaknesses
8.3 Roche Diagnostics
8.3.1 Company Overview
8.3.2 Product Offering
8.3.3 Financial Overview
8.3.4 Key Activities
8.3.5 Strengths and Weaknesses
8.4 Myriad Genetics
8.4.1 Company Overview
8.4.2 Product Offering
8.4.3 Financial Overview
8.4.4 Key Activities
8.4.5 Strengths and Weaknesses
8.5 Life Technologies Corporation
8.5.1 Company Overview
8.5.2 Product Offering
8.5.3 Financial Overview
8.5.4 Key Activities
8.5.5 Strengths and Weaknesses
8.6 Genomic Health
8.6.1 Company Overview
8.6.2 Product Offering
8.6.3 Financial Overview
8.6.4 Key Activities
8.6.5 Strengths and Weaknesses
8.7 Sequenom
8.7.1 Company Overview
8.7.2 Product Offering
8.7.3 Financial Overview
8.7.4 Key Activities
8.7.5 Strengths and Weaknesses
8.8 Transgenomic
8.8.1 Company Overview
8.8.2 Product Offering
8.8.3 Financial Overview
8.8.4 Key Activities
8.8.5 Strengths and Weaknesses
8.9 Dako (Agilent Technologies)
8.9.1 Company Overview
8.9.2 Product Offering
8.9.3 Financial Overview
8.9.4 Key Activities
8.9.5 Strengths and Weaknesses
8.10 Gen-Probe (Hologic)
8.10.1 Company Overview
8.10.2 Product Offering
8.10.3 Financial Overview
8.10.4 Key Activities
8.10.5 Strengths and Weaknesses
8.11 Quest Diagnostics
8.11.1 Company Overview
8.11.2 Products Offerings
8.11.3 Financial Overview
8.11.4 Key Activities
8.11.5 Strengths and Weaknesses
8.12 Genoptix (Novartis)
8.12.1 Company Overview
8.12.2 Product Offerings
8.12.3 Financial Overview
8.12.4 Key Activities
8.12.5 Strengths and Weaknesses
8.13 Clarient (GE Healthcare)
8.13.1 Company Overview
8.13.2 Product Offerings
8.13.3 Financial Overview
8.13.4 Key Activities
8.13.5 Strengths and Weaknesses

List of Figures:

Figure 4-1: Molecular Diagnostics Market (Billion US$), 2008-2011
Figure 4-2: Genetic Testing Market (Billion US$), 2008-2011
Figure 4-3: Forecast for Molecular Diagnostics Market (Billion US$), 2012-2015
Figure 4-4: Forecast for Genetic Testing Market (Billion US$), 2012-2015
Figure 4-5: Number of Companies in Biochemical DTC Genetic Testing Segment (2007-2010)
Figure 4-6: Number of DTC Genetic Testing Companies by Country
Figure 6-1: Number of Laboratories and Diseases for Genetic Testing (1993-2010)
Figure 7-1: Global - Next Generation Sequencing Market (Billion US$), 2011-2015
Figure 7-2: Global - NGS Application by Sector (%)
Figure 7-3: Global - Next Generation Sequencing Market by Player (%), 2010
Figure 8-1: Abbott Laboratories - Revenue Breakup by Geography (%), 2011
Figure 8-2: Abbott Laboratories - Share of MDx Products in Diagnostics Revenue (2011)
Figure 8-3: Beckman Coulter - Revenue Breakup by Geography (%), 2010
Figure 8-4: Beckman Coulter - Revenue Breakup by Business Segment (%), 2010
Figure 8-5: Roche Holding - Diagnostic Division Revenue Breakup by Geography of (%), 2011
Figure 8-6: Roche Holding - Revenue Breakup by Diagnostics Division (%), 2011
Figure 8-7: Myriad Genetics - Revenue Breakup by Business Segment (%), 2012
Figure 8-8: Life Technologies - Revenue Breakup by Geography (%), 2011
Figure 8-9: Life Technologies - Revenue Breakup by Business Segment (%), 2011
Figure 8-10: Sequenom - Revenue Breakup by Business Segment (%), 2011
Figure 8-11: Transgenomic - Revenue Breakup by Geography (%), 2011
Figure 8-12: Transgenomic - Revenue Breakup by Business Segment (%), 2011
Figure 8-13: Dako - Revenue Breakup by Geography (%), 2011
Figure 8-14: Gen-Probe, Inc. - Revenue Breakup by Geography (%), 2011
Figure 8-15: Gen-Probe, Inc. - Revenue Breakup by Business Segment (%), 2011
Figure 8-16: Quest Diagnostics - Revenue Breakup by Business Segment (%), 2011

List of Tables:

Table 4-1: Genetic Testing Labs Penetration in Key Countries
Table 4-2: Key Companies in DTC Genetic Testing Segment
Table 5-1: Test Availability and Market Size for Key Conditions
Table 7-1: Listed Pharmacogenomic Biomarkers in FDA Approved Cancer Therapy Labels
Table 8-1: Abbott Molecular - Key Gene Based Product(s)
Table 8-2: Abbott Laboratories - Financial Performance (Million US$), 2009-2011
Table 8-3: Beckman Coulter - Key Gene Based Product(s)
Table 8-4: Beckman Coulter - Financial Performance (Million US$), 2008-2010
Table 8-5: Roche Molecular Diagnostics - Key Gene Based Product(s)
Table 8-6: Roche Holding - Financial Performance (Million US$), 2009-2011
Table 8-7: Myriad Genetics - Key Gene Based Product(s)
Table 8-8: Myriad Genetics - Financial Performance (Million US$), 2009-2012
Table 8-9: Life Technologies - Key Gene Based Product(s)
Table 8-10: Life Technologies - Financial Performance (Million US$), 2009-2011
Table 8-11: Genomic Health - Key Gene Based Product(s)
Table 8-12: Genomic Health - Financial Performance (Million US$), 2009-2011
Table 8-13: Sequenom - Key Gene Based Product(s)
Table 8-14: Sequenom - Financial Performance (Million US$), 2009-2011
Table 8-15: Transgenomic - Financial Performance (Million US$), 2009-2011
Table 8-16: Dako - Key Gene Based Product(s)
Table 8-17: Dako - Financial Performance (Million DKK), 2009-2011
Table 8-18: Gen-Probe, Inc. - Key Gene Based Product(s)
Table 8-19: Gen-Probe, Inc. - Financial Performance (Million US$), 2009-2011
Table 8-20: Quest Diagnostics - Key Gene Based Product(s)/Service(s)
Table 8-21: Quest Diagnostics - Financial Performance (Million US$), 2009-2011
Table 8-22: Genoptix - Key Gene Based Service(s)
Table 8-23: Genoptix - Financial Performance (Million US$), 2007-2009
Table 8-24: Clarient - Key Gene Based Service(s)
Table 8-25: Clarient - Financial Performance (Million US$), 2007-2009

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Next-generation Sequencing Market

Global Next-generation Sequencing Market

  • $ 10 000
  • Industry report
  • June 2014
  • by Frost & Sullivan

On the Verge of a Quadrupled Competitor Size and a Clinical Turning Point The total market, as defined by this study, includes next-generation sequencing instruments and reagents. Instruments include those ...

Biomarkers: Technologies and Global Markets

Biomarkers: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

REPORT HIGHLIGHTS The global biomarkers market is expected to grow from $29.3 billion in 2013 to $53.6 billion in 2018, a compound annual growth rate (CAGR) of 12.8%. This report provides: An overview ...

Top Technologies in Health and Wellness

Top Technologies in Health and Wellness

  • $ 6 500
  • Industry report
  • March 2014
  • by Frost & Sullivan

The Technical Insights division of Frost & Sullivan evaluated technology trends in the Health and Wellness sector and has identified top technology trends that are likely to have an impact in 2014. The ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.